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ABSTRACT Obesity will continue to be one of the leading
causes of chronic disease unless the ongoing rise in the
prevalence of this condition is reversed. Accumulating morbid-
ity figures and a shortage of effective drugs have generated
substantial research activity with several molecular targets being
investigated. However, pharmacological modulation of body
weight is extremely complex, since it is essentially a battle
against one of the strongest human instincts and highly efficient
mechanisms of energy uptake and storage. This review
provides an overview of the different molecular strategies
intended to lower body weight or adipose tissue mass.
Weight-loss drugs in development include molecules intended
to reduce the absorption of lipids from the GI tract, various
ways to limit food intake, and compounds that increase energy
expenditure or reduce adipose tissue size. A number of new
preparations, including combinations of the existing drugs
topiramate plus phentermine, bupropion plus naltrexone, and
the selective 5-HT2C agonist lorcaserin have recently been filed
for approval. Behind these leading candidates are several other
potentially promising compounds and combinations currently
undergoing phase II and III testing. Some interesting targets
further on the horizon are also discussed.
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ABBREVIATIONS
5-HT serotonin (5-hydroxytryptamine)
11β-HSD1 11-β hydroxysteroid dehydrogenase type 1
AgRP agouti-related protein
β3AR β3-adrenoceptors
BAT brown adipose tissue
BMI body mass index
CART cocaine-amphetamine-regulated transcript
CB1 cannabinoid receptor type 1
CCK cholecystokinin
CNS central nervous system
DGAT diacylglycerol O-acyltransferase
DPP-IV dipeptidyl peptidase IV
EEC entero-endocrine cell
GABA gamma-amino butyrate
GH growth hormone
GI gastro-intestinal
GLP-1 glucagon-like peptide 1
HPA(-axis) hypothalamic–pituitary–adrenal (-axis)
MCH melanine-concentrating hormone
MGAT 2-acylglycerol O-acyltransferase
MSH melanocyte-stimulating hormone
MTP microsomal triglyceride transfer protein
NPY neuropeptide Y
OXM oxyntomodulin
POMC pro-opiomelanocortin
PP pancreatic polypeptide
PPAR γ peroxisome proliferator-activated receptor-γ
PYY peptide YY
SGLT2 (low affinity) sodium-dependent glucose
co-transporter
TRPV type 1 transient receptor potential cation channel V
type 1
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INTRODUCTION—HEALTH RISKS OF BODY FAT
Obesity has become a serious and worldwide public health
problem with important consequences for healthcare costs
(1–3). The common way to classify obesity is by body mass
index (BMI), which is calculated as weight in kg/height in
meters squared. Persons with a BMI over 25 are called
overweight, whereas a BMI of over 30 represents obesity.
Both classifications are major risk factors for a cluster of
health complications often referred to as the metabolic
syndrome (1,4,5). These include (pre-)diabetes type 2,
hypertension and other cardiovascular complications. In
addition, obesity leads to an elevated risk for developing
other diseases, such as non-alcoholic fatty liver disease,
osteoarthritis, sleep apnea, cognitive decline and certain
forms of cancer (6). Although BMI remains a useful general
indicator for health risk, particularly at a population level, it
has become clear that health complications are largely
dependent on the localization and activity of the different
fat depots. For any given amount of total body fat, those
individuals with a predominant excess of intra-abdominal
or visceral adipose tissue are at substantially higher risk of
becoming insulin resistant or getting any of the other
features of the metabolic syndrome (4,7,8). Therefore, waist
circumference or waist/hip ratio is often a better indicator
than BMI (9,10). Furthermore, there remains a risk of
under diagnosis, since persons who look “thin outside” but
have relatively much fat “hidden” within organs, such as
muscles, heart and liver (“fat inside”), bear considerable
health risks (11,12). Within fat tissue, the adipocyte
phenotypes and infiltration of immune cells are considered
pivotal determinants for the development of metabolic
complications (13,14). It has been shown that adipose tissue
can initiate and maintain a low-grade inflammatory
process, which in turn activates inflammatory responses in
liver and other organs. Another important risk factor is the
presence of high levels of free fatty acids in plasma (15,16).
Taken together, it is understandable that the problem of
adiposity has boosted considerable activity in pharmaceu-
tical development, which is often going far beyond
achieving or maintaining a healthy body weight only.
Fig. 1 illustrates the great diversity in potential targets.
Fig. 1 Schematic representation of potential strategies and targets as discussed in this review, to reduce food intake, body weight or adipose tissue mass.
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In Table I, the potential approaches have been catego-
rized into the most important areas of research and
development.
Basically, the first three categories primarily target body
weight, which is the focus of this review. However, there is
not always a sharp division between reduction of weight or
reduction of complications as primary goal, while combin-
ing these objectives also offers advantages. Specifically
modulating metabolic or immunological processes associat-
ed with adiposity is considered potentially effective to
reduce health complications. An interesting example is the
approach to reduce the pro-inflammatory state in over-
weight and obese persons using anti-inflammatory com-
pounds such as salsalate (17–19). In addition, strategies
aiming to modulate body fat distribution and not primarily
total body fat are being investigated. This is based on the
observation that persons with a predominant android
(“apple”) body shape are at higher risk for cardiovascular
disease than persons having a more gynaeoid (“pear”) body
shape. Obviously, genetic and hormonal factors play a role
(20,21). Furthermore, fat cell size may be of importance
(22). Finally, the discovery that regular physical exercise
significantly reduces health risks even in the absence of
direct weight reduction (1,23–25) has stimulated the
research on an “exercise pill” (24,26–28).
WEIGHT MANAGEMENT DRUGS—ISSUES
AND NEEDS
While keeping in mind that health risks are not simply
determined by body weight or even total body fat mass,
losing weight is still commonly regarded as effective in
overweight people who are developing symptoms of the
(pre-)metabolic syndrome. Ideally, weight management
should be based on lifestyle modification, including the
reduction of caloric intake, increased activity, and physical
exercise. Unfortunately, long-term effects of diet or exercise
on weight are often disappointing. The desire to eat is one
of the strongest instincts, and humans have developed
powerful mechanisms to guard against starvation during
periods of food scarcity. Our brains do not only generate
sensations of hunger as a result of direct metabolic
stimulation. Instead, human eating behavior is a combina-
tion of liking (hedonic impact), wanting (incentive
motivation), and learning (associations and predictions)
(29–31). Non-homeostatic overeating is regulated by central
dopaminergic, serotonergic, opioid and cannabinoid sys-
tems that show many interconnections and overlaps with
other important regulatory pathways (32,33). As a result,
the development of effective drugs with acceptable side-
effects can be very cumbersome. With respect to durable
weight reduction, bariatric surgery is the most effective
long-term treatment for severe obesity with the greatest
chances for amelioration and even resolution of obesity-
associated complications, including diabetes (34,35). How-
ever, depending on the technique used, it is not without
surgical risks or metabolic complications (35) and involves
high costs. Pharmacological options are to be considered as
an adjunct to dietary measures and physical exercise, and
long-term weight management by drug treatment alone
does not seem realistic at present. However, there will be
situations where the use of drugs or possibly even vaccines
to reduce weight is medically rational and justified. Criteria
for FDA approval of anti-obesity drugs prescribe that 35%
of treated persons must lose at least 5% of their body
weight, and that group should include at least twice as
many individuals as the number of patients who achieve a
similar weight loss on placebo. Alternatively, the therapy
must result in at least 5% placebo-corrected weight loss. On
a population level, such figures will contribute to a lower
incidence of complications. The history of development and
application of weight loss drugs has shown to be trouble-
some and characterized by many failures and withdrawals.
The most recent example of this occurred in January 2010,
when subitramine was suspended from the European
market by EMA (www.ema.europe.eu) because of potential
cardiovascular risks in certain patients. The compound has
remained available in the US, but the FDA issued a safety
notification and requested a new contraindication stating
that sibutramine should not be used in patients with a
history of cardiovascular disease. Another recent case was
the suspension of the cannabinoid receptor type 1 (CB1)
inverse agonist rimonabant from the EU market in October
2008. At that time, FDA had not given approval for the
compound because of doubts regarding its CNS risk-benefit
profile. While preparing this review (October 2010) the
FDA raised serious concerns on the new applications for
lorcaserin and the new phentermine/topiramate combina-
tion. In 1997, fenfluramine and dexfenfluramine, particu-
larly popular with phentermine in fen-phen combinations,
were withdrawn after reports of negative effects on heart
valves and primary pulmonary hypertension (36). The
historical list of failures and withdrawals further continues
Table I General Pharmacological Strategies to Combat Overweight or
Complications of Adiposity
• Reducing energy absorption from the GI tract or peripheral tissues
• Decreasing food consumption by increasing satiety or satiation, reducing
appetite, increasing feelings of reward, etc.
• Reducing body fat by stimulating energy expenditure or inhibiting energy
supply of adipose tissue
• Reducing inflammatory activity of adipose tissues
• Modulating body fat distribution, energy fluxes or mimicking physical
exercise
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with thyroid preparations, ephedrine, dinitrophenol, etc.
Despite many efforts to bring new compounds to the
market, the intestinal lipase inhibitor orlistat has remained
the only compound that is currently approved both in the
US and in Europe. However, some new drugs appear to be
close to approval, and it is obvious that the pharmacology
of weight management remains a highly challenging area
for industry and academia. It also represents a multi-billion-
dollar market, and several research groups are heavily
engaged in finding new targets and molecules. The history
of discovery of anti-obesity drugs is also characterized by
much serendipity. As described further, some of the most
advanced preparations currently in the pipeline are based
on compounds or drug targets that were originally found
for other indications.
STRATEGIES TO REDUCE ENERGY
(RE-)ABSORPTION
Reducing the uptake of energy-rich molecules from the GI
tract, preferably by locally acting compounds, could be an
attractive approach, since this would minimize the risks of
systemic side-effects. Indeed, the lipase inhibitor orlistat
belongs to the very few compounds having survived so far.
This is also a suggested mechanism of action of many food
supplements advertised for weight management. Several of
these preparations claim to bind fat in the GI tract,
including chitosan, glucomannan, psyllium seeds, etc.
However, there seems to be little evidence for sustained
efficacy in humans of these products (37). A new lipase
inhibitor, cetilistat, is now in an advanced stage of
development. In addition, a number of new targets are
evolving, including inhibitors of Microsomal Triglyceride
transfer Protein (MTP) and Diacylglycerol O-
acyltransferase (DGAT). A related but different category
comprises the inhibitors of low-affinity sodium-dependent
glucose co-transporters (SGLT2). Acting by blocking
glucose re-absorption in the kidneys and originally devel-
oped for diabetes, some are now in trials for obesity.
Farther on the horizon are strategies aiming to modulate
GI metabolism.
Inhibitors of Pancreatic Lipase
Pancreatic lipase is one of the exocrine enzymes of
pancreatic juice and is essential for digestion and absorption
of dietary fats. Orlistat (Fig. 2) is the tetrahydro-derivative of
the natural compound lipstatin, produced by the microor-
ganism Streptomyces toxytricini (38). Orlistat has shown to be
effective in reducing body weight, leading to 5–10% weight
loss in 50–60% of patients. In clinical trials, this loss (and
related clinical benefits) has shown to be maintained up to at
least four years. A typical side effect of the compound is
steatorrhoea (fecal fat loss). The compound is also sold in an
OTC preparation in a lower dose compared to the
prescription form. Recently, concerns have been raised
concerning potential liver damage in orlistat users. In August
2009, the FDA posted an early communication about an
ongoing safety review on orlistat (39).
Cetilistat (= ATL-962, Fig. 2) is a newly developed lipase
inhibitor which has recently entered phase III clinical
testing. It has been suggested that the compound is equally
effective as orlistat while producing fewer GI side effects
Fig. 2 Chemical structures of the
lipase inhibitors orlistat (an ap-
proved drug) and cetilistat
(currently in development).
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(40). However, more long-term studies on the side effects
and efficacy of cetilistat are required in order to confirm
this and to answer the question whether GI side effects,
such as steatorrhoea, are inevitably connected to the
mechanism of action of this class. Another lipase inhibitor,
called GT 389-255, was under development by Peptimmune,
under a license from Genzyme. It was designed as a
combination of an (undisclosed) lipase inhibitor and a
polymer aiming to bind undigested triglycerides. This should
allow increased fat excretion without the side effects of
conventional lipase inhibitors. However, the development
seems to be stalled or stopped, as there were no further clinical
studies reported since the phase I trials conducted in 2004.
Inhibitors of Intestinal Microsomal Triglyceride
Transfer Protein (MTP)
Microsomal triglyceride transfer protein (MTP) is an
essential chaperone for the assembly of apolipoprotein B
(apoB) (see (41) for recent review). The clinical utility of
small-molecule MTP inhibitors to reduce plasma lipids
was originally held up by their potential to induce
hepatic steatosis, caused by inhibition of the hepatic
form of MTP. However, further research led to the
discovery of gut selective MTP inhibitors, which pre-
dominantly act on the enterocytic form of MTP. This
was achieved by compounds that are poorly absorbed or
extensively metabolized to inactive metabolites (such as
JNJ-16269110). A number of compounds have resulted
from this development, but at this stage, their therapeutic
potential is not yet clear. The company Aegerion is
currently developing EGR-773, lomitapide (previously
BMS-201038, Fig. 3) for the treatment of familial
hypercholesterolemia, but apparently not for obesity.
Pfizer stopped the development of their molecule dirlota-
pide (Fig. 3) for human use and subsequently launched it
in 2007 as the first drug approved for weight management
in dogs. Surface Logix (http://www.surfacelogix.com) is
currently working on SLx-4090 (structure not disclosed)
for various indications, apparently including weight loss.
The compound is presently in phase II. Johnson and
Johnson recently reported a trial with their new MTP
inhibitor JNJ-16269110 in 321 non-diabetic obese sub-
jects. A dose-dependent weight loss of approximately 1.5–
3.5% (corrected for placebo) was obtained after 12 weeks
of treatment (42). No significant side effects were reported,
and treatment apparently did not lead to unpleasant fecal
fat loss.
DGAT1 and MGAT Inhibitors
Diacylglycerol O-acyltransferase (DGAT; EC 2.3.1.20) catalyzes
the last step of triacylgycerol synthesis. See (43) and (44) for
reviews. DGAT is expressed in different tissues, including
liver and white adipose tissue. Two isozymes of DGAT,
DGAT1 and DGAT2, have been described so far
(http://www.uniprot.org/uniprot). Increased DGAT2 ac-
tivity has a role in steatosis, while DGAT1 plays a role in
VLDL assembly. Increased plasma VLDL concentrations
may promote obesity; thus, DGAT1 is considered a
potential therapeutic target for obesity control. Pfizer
recently (2010) finalized a phase I trial (Clintrial.gov
NCT01064492) with their DGAT1 inhibitor PF
04620110 that is initially being developed for the
treatment of type 2 diabetes mellitus. The company
anticipates that the compound will have anti-diabetic
effects through inhibition of intestinal triglyceride absorp-
tion and will potentially cause weight loss. AstraZeneca
(www.astrazeneca.com) also report a DGAT1 inhibitor in
development for diabetes/obesity in their July 2010
pipeline overview (45).
MGAT (MOGT 2; 2-acylglycerol O-acyltransferase 2;
EC 2.3.1.22) catalyzes the formation of diacylglycerol from
2-monoacylglycerol and fatty acyl-CoA. It belongs to the
diacylglycerol acyltransferase family (43,44). It is highly
expressed in liver, small intestine, colon, stomach and
kidney and plays a central role in absorption of dietary fat
in the small intestine by catalyzing the re-synthesis of
triacylglycerol in enterocytes. It is considered a potential
target for weight loss, although concern has been raised
because of the theoretical accumulation of fatty acids and
monoacylglycerol in enterocytes. Probably due to this,
MGAT gets less attention compared to SGAT, and its
future as drug target seems uncertain.
Fig. 3 Chemical structures of two representative MTP inhibitors:
dirlotapide and lomitapide.
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Inhibitors of Low-Affinity Sodium-Dependent Glucose
Co-transporters (SGLT2)
Compared to the previous categories discussed, this target
represents a different potential approach for weight loss.
The sodium-glucose co-transporter-2 (SGLT2) is a low-
affinity transport system that is specifically expressed in the
kidney and plays an important role in renal glucose re-
absorption in the proximal tubule. Competitive inhibition
of SGLT2, leading to enhanced glucose and energy loss
through the urine, was initially regarded a promising new
therapeutic strategy for the treatment of hyperglycaemia in
patients with type 1 or type 2 diabetes (see (46) for a recent
review). However, some compounds are now also under-
going investigation for their potential effect on body weight.
These include serglifozin (GSK-869682; clintrials.gov
NCT00297180), canaglifozin (JNJ-28431754; clintrials.gov
NCT00650806) and remogliflozin etabonate (GSK-
189075; clintrials.gov NCT00494767). Johnson and John-
son plan to file their canaglifozine before 2013 (47).
Intestinal Microbiota as Future Target for Weight
Management?
A potential future strategy for weight loss that is currently
receiving increasing attention is selective modulation of the
intestinal micro flora. Some years ago, Gordon and co-
workers (48,49) discovered that intestinal bacteria appear to
have an important effect on body weight. In addition,
certain antibiotics can increase body weight in rats and
mice, and human data indicate that the combination of
vancomycin plus gentamycin is accompanied by a signifi-
cant weight gain (50). Several mechanisms have been
suggested, including the phenomenon of “energy harvest-
ing” by the micro flora, production of specific short-chain
fatty acids interacting with certain receptors including
GPR41 and GPR43 (51), and changes in the pro-/anti-
inflammatory balance in the gut.
TARGETS FOR REDUCING APPETITE
OR INDUCING SATIETY OR SATIATION
Pharmacological modulation of human eating behavior has
proven to be extremely complex. People do not only eat to
satisfy their hunger or appetite, but also for many other
reasons, including sensory stimulation, sensory hedonics, in
response to stress, for social interaction, against boredom,
etc. (29–31,52,53). Several pathways are involved in
regulating eating behavior with many redundant and
compensation mechanisms in place. Before and during
eating, sensory effects are generated through the taste,
smell, temperature and texture of food. Cognitive effects
play a role in the beliefs about the properties of the foods
being eaten and their effects. Post-ingestive factors include
the effects of gastric distension, rate of gastric emptying,
release of intestinal hormones into the circulation and
neural signaling via the Nervus vagus (see (54) for review).
Signals and hormones originating from the GI tract are
commonly called satiety signals and satiety hormones,
respectively. They include the pancreatic hormone gluca-
gon, cholecystokinin (CCK), GLP-1, PYY, etc. It should be
noted that the term satiety hormones may be somewhat
confusing, since most of them promote a process called
satiation, which serves as trigger of meal termination. Meal
termination is also stimulated by circulating levels of
glucose, amino acids and lipids, which are directly sensed
by the brain or through peripheral receptors (55). By
contrast, the term satiety is typically used to describe
processes that inhibit further eating during postprandial
periods, determining meal frequency. Blood glucose con-
centration activates gluco-receptors in the hypothalamus,
either acting to up-regulate hunger when blood glucose
levels fall or up-regulate satiety when glucose concentra-
tions rise. In the longer term, deposition of fat may lead to
control of appetite by neuronal and hormonal signals via
leptin. Within the central nervous system, systems involved
in eating behavior share many mediators and pathways
involved in, for example, the regulation of metabolism and
mood state. This partly explains why several compounds
with a relatively broad spectrum of activities have shown
unacceptable side effects in the past. Vice versa, there are also
several CNS drugs developed for other indications that
show effects on eating behavior.
For the purpose of this review, two main approaches will
be distinguished here:
– Modulation of nutrient sensing within the GI tract or
through interference with signals transmitted to the
brain or peripheral organs.
– Modulation of signal processing within the CNS, for
example by interfering with neurotransmitter concen-
trations or activity.
NUTRIENT SENSING WITHIN THE GI TRACT
AND SIGNALLING TO THE BRAIN
Generation of Satiety Signals in the GI Tract
According to most of the present views, endocrine
biochemical signals are not regarded as major drivers for
meal onset. So far, the only exception seems to be ghrelin,
which is an orexigenic (stimulating eating) peptide hor-
mone, surging just before meals and suppressed by ingested
nutrients (54,56). By contrast, satiation is a process that is
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delicately regulated by various signals originating from the
stomach and gut. Along the GI tract, several receptor types
are present that respond to nutrients and their immediate
breakdown products, such as amino acids, small peptides,
fatty acids or carbohydrates (51). Increasing evidence
suggests that metabolites formed by bacteria or host cells
within the GI tract are also involved in this sensing process
(51). Receptors are located on so-called entero-endocrine
cells (EECs) and on afferent nerve terminals (see also
Fig. 1). By their shape and location, these entero-endocrine
cells are well equipped to sense chemical structures in the
lumen and to pass their information to small blood vessel
and nerve terminals. Their apical side is in contact with the
luminal contents, and their basolateral side is in contact with
the vasculature of the lamina propria, neural cells, and with
distant enterocytes. Remarkably, several entero-endocrine
cell types throughout the gut also express taste receptors,
including T1R2/3 sweet taste receptors, T2R-family bitter
receptors, and the taste-specific G protein Gα-gustducin
(57,58). An important finding has been that taste-like
nutrient sensing is necessary for normal GLP-1 secretion.
Expression of sweet taste receptors was also found to be
decreased in diabetic subjects with elevated blood glucose
concentration (58). In addition, endocannabinoids induce
sweet taste (59). This suggests that intestinal “taste”
signaling is under dynamic metabolic and luminal control.
Nutrient signaling to the brain is a combination of
endocrine and neural processes. Vagal afferent nerve fibers
are forming the enteric nervous system, which communi-
cates to the brain via the N. Vagus. Nerve terminals in the
mucosa contain specific receptors that recognize satiation
peptides and nutrient-derived mediators (60).
Upon stimulation, several satiation-inducing peptides are
being released by entero-endocrine cells, including chole-
cystokinin (CCK), bombesin, glucagon, glucagon-like
peptide-1 (GLP-1), GLP-2, apolipoprotein A-IV, amylin,
somatostatin, enterostatin, and peptide YY (PYY). Increas-
ing evidence suggests that the development of satiation
cannot be simply attributed to stimulation of specific
receptors at defined locations. Instead, digestion, passage
through the GI tract and satiation are acting in a cascade of
events. Sensing and feedback occur via signals from
multiple sites in the GI system, including the stomach,
proximal small intestine, distal small intestine, colon, and
pancreas (52,54).
Satiation signals also interact with adiposity signals, in
which leptin plays an important role. The central integra-
tion and control occurs by the hypothalamus, which is
continuously informed about the nutritional, energetic and
environmental status of the body. This complexity in
signaling and cross-talk has often limited the clinical result
of a single target drug, i.e. a molecule specifically acting on
one receptor.
Intestinal, Pancreatic and Peripheral Receptors
and Local Feed-Back Mechanisms as Potential Targets
for Satiation
Considering the abundance and diversity of nutrient-
sensing receptors, it is understandable that they are
receiving considerable interest as potential targets for
satiety induction. This is also obvious from the high activity
in the patent literature. Many GI receptors still have an
orphan receptor status, but considerable progress is being
made with their de-orphanization and characterization.
The gut contains several types of receptors, for example G-
protein gustducin and G-protein-coupled receptors (includ-
ing GPR119, 93, 55,120 and 40), TRPV type 1, and
various other types including melanocortin, opioid and
PPAR (51,58,61–66). So far, intensive research for phar-
macological ligands that possess significant effects on body
weight has not led to important breakthroughs. An
interesting exception to this seems to be the G-protein-
coupled receptor GPR 119. Initially, GPR119 was consid-
ered a potential new endocannabinoid receptor because of
structural similarity and overlapping ligand selectively.
Two of the major endogenous ligands discovered so far
are the fatty acid amides oleylethanolamide (OEA, Fig. 4)
and N-oleoyldopamine (Fig. 4), which were originally also
classified as endocannabinoids. The process of de-
orphanization of GPR119 and the demonstration that
small molecule agonists are able to reduce body weight
gain in rodents was first published in 2006 by Overton et al.
(67) from OSI Pharmaceuticals (now Astellas). The receptor
was shown to be Gαs-protein coupled and predominantly
expressed in pancreatic islets and gastrointestinal tract in
humans and rodents. GPR119 agonists were found to
increase intracellular cAMP, which in turn leads to
increased GLP-1 secretion from entero-endocrine cells
(67–69). Very recently, it was shown that there is also
cross-talk between the satiety hormone PYY and the
GPR119 receptor (60). Together, these discoveries have
generated considerable interest in the search for small-
molecule GPR119 agonists as potential inducers of satia-
tion, which is also illustrated by the robust activity in the
patent area (70). Following the synthesis of the first ligands,
including PSN632408 and AR-231,453 (Fig. 4), several
pharmaceutical companies became active in developing
GPR119 agonists and report activity from time to time.
More examples and structures are available through the
literature (70–72). Many of these compounds have shown
interesting activities in animal models of type 2 diabetes
and obesity, including a reduction of blood glucose without
causing hypoglycaemia, a reduction of food intake and
body weight, and reduced diabetes progression (69). The
first compound that was advanced to the clinic, APD-668,
was co-developed by Arena Pharmaceuticals (http://www.
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arenapharm.com) and Ortho McNeil. It showed improve-
ment of glucose control in diabetic patients. Nevertheless,
the partners chose to give priority to the related compound
APD-597 (structure not disclosed), which is now in phase I.
Apparently, diabetes is the primary indication at this moment
(73). Metabolex (www.metabolex.com) initiated a phase I trial
with MBX-2982 (structure not disclosed) in March 2008; in
November 2008, phase Ia data were presented. The drug
was rapidly absorbed and showed a half-life allowing once-
daily dosing. MBX-2982 also caused dose-dependent reduc-
tions in glucose and increased GLP-1 following a mixed meal.
The compound is now further developed together for
diabetes with Sanofi-Aventis (74). OSI pharmaceuticals is
currently in phase II with PSN-821. Taken together, study
results with GPR119 agonists are encouraging.
The Endocannabinoid System: Not a Lost Target
The endocannabinoid system modulates food intake and
energy metabolism at different levels, starting from recep-
tors within the GI tract to the regulation of hedonic
rewarding in the brain (33,75). It is regarded as a distinctive
Fig. 4 Some GPR119 ligands;
the endogenous fatty acid amides
oleylethanolamide (OEA) and N-
oleoyldopamine (ODA), and two
synthetic compounds :
PSN632408 and AR-231453.
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pleiotropic regulator of energy uptake and storage and of non-
homeostatic eating behavior (76,77). In the past, these
mechanisms were beneficial in order to survive periods of
food shortage. The first generation CB1 blockers, including
rimonabant, were reverse agonists developed to act on
receptors present within the CNS. Later, it became clear that
CB1 receptors were also present outside the CNS. Further-
more, it is now assumed that the central effects of rimonabant
are responsible for the short-term reduction of food-intake,
whereas the more sustained effects on body weight and the
improvement of insulin resistance and blood lipids are more
due to its peripheral actions. The failure of rimonabant
because of depression-related side effects in predisposed
persons shocked the pharma industry. By the end of 2008, at
least nine companies terminated active development projects
with CB1 blockers, including some with compounds in a well-
advanced stage of development such as taranabant (Merck)
and CP-945,598 (otanabant, Pfizer). However, interest in CB1
modulation in relation to metabolic diseases has not complete-
ly disappeared (76,78), and, in principle, a number of
therapeutic options have remained. These include the use
of CB1 neutral antagonists or partial agonists as opposed to
reverse agonists, such as rimonabant, or by using so-called
peripherally restricted CB1 antagonists (78–83). Several
peripherally restricted CB1 blockers have been synthesized
and characterized (82,84,85). These second-generation CB1
blockers are more lipophilic, leading to lower brain concen-
trations. Some compounds have shown sustained effect on
weight without giving the temporal suppression of food intake
seen with rimonabant (82,84,85). Fig. 5 shows some
examples. LH-21 (84) was one of the first compounds
described in this class, and the 7-carbamoylmethyl-pyrazole-
carboximide derivatives have been synthesized by Danish
7TM Pharma (85). In early 2010, 7TM Pharma announced
that it had successfully completed a phase I clinical trial with
the drug candidate TM38837 showing favorable pharmaco-
kinetic properties in humans (86).
Compounds Interfering with Signaling Pathways
to the Brain
As earlier described, satiety signals from the gut are
transferred to the brain via neural pathways and through
the circulation via peptide hormones. The latter offers
options for pharmacological intervention, which in some
cases has provided effective approaches. Some examples
are listed in Table II.
Amylin Analogues
Amylin is a peptide of 37 amino acids which is co-released
with insulin by the pancreas (56,87). Its primary sites of
action are thought to be located in the brainstem. Amylin
analogues were originally developed for therapeutic use in
diabetes but were also shown to cause weight loss, for
example in obese patients with type 2 diabetes (88). The use
of the endogenous peptide might increase the risk for the
formation of amyloid fibrils (56). However, the analogue
pramlintide (Symlin®, Pubchem CID 16132446), devel-
oped by Amylin Pharmaceuticals, does not contain the
sequence that is considered responsible for this effect.
Pramlintide is already available in the US as an injectable
antihyperglycemic drug for diabetic patients who also use
insulin. An interesting preparation which is currently in
development is the combination of pramlintide with
metreleptin (89). Metreleptin is a synthetic analogue of
Fig. 5 Chemical structure of rimonabant, the first clinically developed CB1
blocker, which failed during (US) and after (EU) registration and some
examples of second-generation CB1 blockers. While LH-21 has not been
developed into the clinic, compounds belonging to the 7-carbamoylmethyl-
pyrazole-carboximide derivatives are still in development.
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leptin. Normally, sensitivity to leptin is reduced in obesity,
which limits its therapeutic potential. However, pramlintide
was found to inhibit this process. In a 20-week trial, the
combination induced a weight loss of 12.7±0.9% (11.5±
0.9 kg) in obese persons (89). Another second-generation
amylin analogue in development was davalintide (30).
However, recently, Amylin Pharmaceuticals and Takeda
(Japan) announced they were giving priority to the pramlin-
tide/metreleptin combination and discontinuing develop-
ment of davalintide. Phase II studies demonstrated that the
weight-loss efficacy and tolerability profile of davalintide was
not better than that of pramlintide and was inferior to that of
the pramlintide/metreleptin combination (90).
PYY Analogues
PYY (1–36) is a 36-amino-acid polypeptide synthesized by
entero-endocrine cells of the L-type, mainly in the distal
gut. The main circulating form of the hormone is PYY(3–
36), which is formed after partial cleavage of PYY(1–36) by
dipeptidyl peptidase IV (56). PYY is considered to be a
principal mediator of the ‘ileal brake’ reflex, which is a
feedback mechanism that slows gastric emptying and
intestinal transit in response to nutrients (fat, protein, and
carbohydrates) arriving in the distal small intestine. The
effects of PYY3-36 are mediated via the Y2-receptor, which
is found throughout the central nervous system, in the
nodose ganglion, and on Vagal afferents. It has also been
suggested that weight loss induced by PYY3-36 occurs in
part by modulating energy expenditure and fuel partitioning
(56). Following the discovery of Batterham et al. (91) that
peripheral administration of PYY3-36 can cause a reduction
of food intake in rodents and in obese and normal-weight
humans, other studies confirmed the anorectic action of
PYY3-36. However, in their review, Boggiano et al. (92) take a
very skeptical position on the potential of PYY3-36-based
therapies in practice. A phase II trial in 2008 with a PYY3-
36 nasal spray showed encouraging results (56). Nevertheless,
the development of that formulation was stopped, as the
results did not meet the primary endpoints. At present, there
appears to be little activity with PYY-based approaches (30).
Pancreatic Polypeptide Analogues
Pancreatic polypeptide (PP) is a 36-amino-acid peptide
categorized in the same family as PYY. However, in contrast
to PYY, it is mainly secreted by the pancreas and, to a lesser
extent, by the colon (56). Plasma PP concentrations rise in a
biphasic manner following nutrient ingestion. This increase
is proportional to the caloric load of the meal with
concentrations remaining elevated up to 6 h after a meal.
This suggests that PP exerts its effects on feeding mainly by
inducing satiety. PP has highest affinity for Y4-receptors in
brainstem and hypothalamus, followed by Y1- and Y5-
receptors. Several studies demonstrate that PP can reduce
food intake. Danish 7TM Pharma has developed TM-
30339, a synthetic analogue of PP and a selective Y4-
receptor agonist. The compound demonstrated weight loss
in diet-induced obese mice. According to the company, the
compound showed good safety and tolerability data and is
now in phase II. However, indications have apparently
shifted to gastrointestinal disorders, including mucositis,
malabsorphtion, ulcerative colitis, Crohn’s disease and short
bowel syndrome (93). The same company has also developed
the dual PP and PYY (3–36) analogue obinepitide (http://
www.uniprot.org/uniprot/P01298), with agonist activity
both for the Y2 and Y4 receptor (94). According to 7TM
Pharma, the compound had greater weight-loss-inducing
effects in diet-induced obese mice than PYY3-36. The
compound is now in phase I/II, and once-a-day subcutane-
ous administration in obese subjects inhibited food intake at
a statistically significant level up to 9 h after dosing.
GLP-1 Analogues
Among the gut hormones, GLP-1 is currently the most
promising and advanced target for pharmacological weight
management. Natural GLP-1 is synthesized by intestinal L-
cells and subsequently cleaved to its active fragments GLP-
17–37 and GLP-17–36 amide, the latter being the major
circulating form. GLP-1 is rapidly inactivated by dipeptidyl
peptidase IV (DPP-IV), leading to an elimination half-life of
only 1–2 min. The peptide acts on the GLP-1 receptor,
Table II Some Examples of Pharmacological Interventions Via Gut Hormone Signaling
Gut hormone Approach Example(s)
Amylin Peptide analogues Pramlintide
PYY PYY(3-36) analogues Nasal formulations, development discontinued for the time being
Pancreatic polypeptide PP analogues/Y4 agonists TM-30339, obinepitide (dual-analogue of PYY3-36 and PP)
GLP-1 Stable analogues Exenatide, liraglutide
Oxyntomodulin Analogues ? TKS1225
Ghrelin Vaccination/mRNA aptamers NOX-B11 Spiegelmers
Leptin Analogues (in combinations) Metreleptin-pramlintide combination
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which is widely expressed throughout the CNS and
peripheral tissues (56). GLP-1 receptors in peripheral tissues,
including the stomach, may also be important in meal
termination and possibly satiety. Administration of GLP-1
causes a dose-dependent reduction of food intake in
experimental animals and in both lean and obese humans.
Two main strategies are being followed to combat the
extremely short half-life of native GLP-1. The first is by
producing more stable GLP-1 analogues; the second is by
inhibiting DPP IV, which is catalyzing the GLP-1 break-
down. For weight management, stable GLP-1 has so far
produced the best results. A first breakthrough was the
discovery of the natural GLP-1 analogue exendin-4 in the
venom of a lizard called Gila monster. Based on this
molecule, Amylin Pharmaceuticals and Eli Lilly developed
exenatide (Byetta®), which is already on the market as an
adjunct to current diabetes therapies. The observation that
the drug not only improved glycemic control, but also
caused a reduction in body weight, stimulated further
research in this direction. An unpleasant side effect of
Exenatide is nausea, in particular during the initial phase
of treatment. Furthermore, patients can develop antibodies
to the drug, which sometimes leads to reduced efficacy.
Exenatide needs to be administered twice daily by subcuta-
neous injection, which is also a disadvantage. To overcome
this, a once-weekly injection preparation named exenatide
LAR (Amylin/Lilly/Alkermes) is currently under develop-
ment. Phase III trial results have demonstrated good
blood sugar control and weight loss, especially in patients
for whom metformin or sulphonylureas are not effective
(95). As expected, exenatide LAR has a side-effect profile
similar to Byetta®. A promising alternative is liraglutide
(Novo Nordisk), a GLP-1 analogue with 97% similarity to
human GLP-17–37 (96). Due to the addition of a side
chain, liraglutide binds to albumin, leading to a half-life of
about 13 hours. Liraglutide has already been approved for
use in diabetes. Recently, the NN8022-1807 Study Group
(96) reported the results of a double-blind, placebo-
controlled 20-week trial, with open-label orlistat comparator
in 19 sites across Europe. In total, 564 non-diabetic
individuals with a BMI between 30 and 40 kg/m2
participated. Mean weight loss with the different doses of
liraglutide was between 4.8 and 7.2 kg, compared to 2.8 kg
with placebo and 4.1 kg with orlistat. More individuals
(76%, n=70) lost more than 5% weight with liraglutide
3.0 mg than with placebo (30%, n=29) or orlistat (44%,
n=42). Liraglutide also showed beneficial effects on blood
pressure and pre-diabetes symptoms. Although nausea and
vomiting occurred at higher frequency in the liraglutide
groups, these side effects were considered transient and
rarely led to discontinuation of treatment. As liraglutide still
needs to be administered by injection, Novo is developing a
long-acting oral GLP-1 analog (NN9924) that utilizes
sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)
carrier technology (97). A phase I trial was started early
2010.
Oxyntomodulin (OXM)
OXM consists of 37 amino acids of which 29 are in
common with GLP-1. Levels peak at 30 min and in
proportion to caloric intake, remaining elevated for several
hours (56). Although OXM has a 50-fold lower affinity for
binding at the GLP-1 receptor, it has an equal potency for
inhibiting food intake. Studies have shown that OXM
reduces food intake and causes reduced weight gain in
rodents. Acute OXM administration reduced food intake in
lean volunteers, and chronic OXM subcutaneous injections
in obese individuals induced an average weight loss of
2.3 kg after 4 weeks, compared to 0.5 kg in the control
group (56). Despite this, only a small number of develop-
ment projects appear to be in an advanced stage. Thiakis
Limited (London, UK) started in March 2008 investigating
the potential of their OXM analogue, TKS1225. Following
the take-over of Thiakis by Wyeth in December 2008,
which was in turn acquired by Pfizer in 2010, the present
status of this molecule is unknown.
Cholecystokinin-1 (CCK) Agonists
CCK is secreted by I-cells in the proximal part of the small
intestine. The hormone is formed by post-translational
cleavage of the pre-pro-CCK polypeptide, which undergoes
further proteolysis to a cocktail of active peptides with
varying numbers of amino acids (see (98) for review).
Following nutrient ingestion, circulating CCK levels start to
increase bi-phasically at 15 min, reaching a peak at around
25 min, and remain elevated for approximately 3 h (56).
Presently, there are two G-protein-coupled CCK receptors
known. CCK-1 receptors are mainly present in the
gastrointestinal tract, myenteric plexus and Vagal afferents,
while CCK-2 receptors are predominantly expressed in the
brain. It is widely accepted that CCK-induced satiation is
largely mediated by the CCK-1 receptors (56). Although
administration of CCK has shown to cause a reduction of
food intake, its value for anti-obesity therapy has proven to
be limited so far. It appears that CCK is more important in
satiation than satiety, which could lead to compensation
through increasing meal frequency. GSK has stopped the
development of their compound GI 181771 after phase II
clinical trials failed to show any significant weight loss (99).
A limitation of that study might have been that participants
were allowed to eat ad libitum and might have compensated
their energy intake by increasing meal frequency. At the
end of 2008, Pfizer also discontinued development of a
CCK agonist (CE-326597) after phase II.
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Blocking Ghrelin Activity
In contrast to the previously described gut hormones,
ghrelin stimulates eating. Ghrelin is a 28-amino-acid
polypeptide released from the gastric oxyntic cells. Its
plasma levels show a marked rise shortly before the start
of a meal (100). The peptide increases food intake both in
rodents and humans. Ghrelin has been shown to act on the
growth hormone secretagogue receptor 1A (GHS-R1a),
which is expressed in several brain areas (101). In order to
bind, ghrelin needs to be bio-activated through acylation
with a medium-chain fatty acid. The enzyme involved,
gastric O-acyltransferase (GOAT), has also attracted inter-
est as a potential target to modulate ghrelin activity (102).
Some discussion is remaining on the potential role of non-
acylated ghrelin (56). Recent studies suggest that ghrelin
activates reward-seeking circuits and increases the incentive
value of palatable foods in particular (101). To modulate
ghrelin effects, blocking the receptor using small-molecule
antagonists seems an interesting option. Indeed, several
GHS-R1a blockers were synthesized and characterized (for
example (103,104)). However, no molecules appear to have
reached the clinical phase to date. Alternative strategies are
targeting ghrelin itself by ghrelin RNA aptamers (so-called
Spiegelmers, including NOX-B11) developed by Berlin-
based company NOXXON Pharma AG (105) or by an
anti-ghrelin vaccine (106). The aptamer strategy was
licensed to Pfizer and has not yet reached clinical testing.
Although ghrelin vaccination has shown promising results
in animals (106), human tests have not given suitable results
so far.
Leptin Analogues
Leptin is not a gut hormone but secreted by adipose tissue.
It has been shown to act as both a short- and long-term
regulator of energy balance and to signal in the arcuate
nucleus, where it inhibits NPY/AgRP signaling and
stimulates POMC/CART signaling. After the discovery of
leptin, expectations were high regarding its potential to
reduce appetite. However, early clinical trials of leptin
therapy for the treatment of obesity failed because the
majority of obese patients exhibit leptin resistance. Recent-
ly, though, leptin has reemerged as a targeted antiobesity
therapeutic in combination with the amylin analogue
pramlintide (see section on amylin analogues).
DRUGS ACTING ON NEUROTRANSMISSION
AND RECEPTORS IN THE CNS
The regulation of food intake and body weight within the
central nervous system occurs at different levels with
multiple systems being involved. A detailed description falls
beyond the scope of this article. For recent reviews, see for
example (32,55,107–109). Briefly, different stimuli, includ-
ing satiety hormones, signal coming in via the N. vagus, and
nutrients in plasma are sensed and integrated by the
brainstem and the hypothalamus. In the arcuate nucleus
of the basal hypothalamus, the orexigenic (appetite stimu-
lating) neuropeptide Y (NPY) and agouti-related protein
(AgRP)-expressing neurons counterbalance anorexigenic
pro-opiomelanocortin (POMC) and cocaine-amphetamine-
regulated transcript (CART)-expressing neurons (see also
Fig. 1). Signaling at neuronal Y1 and Y5 receptors produces
the orexigenic effects of NPY, whereas Y2- and Y4-receptor
signaling produces an anorexic phenotype due to their
presynaptic inhibition of NPY release. The latter two
receptors are also the targets of the gut hormones PYY
and PP that have been discussed in the previous section.
The resulting level of metabolic balance in the basal
hypothalamus is integrated with signals from brainstem
centers and input from the lateral hypothalamus and
further projected to so-called second-order hypothalamic
neurons. The liking (pleasure/palatability) and wanting
(appetite/incentive motivation) associated with the in-
creased availability and variety of food are processed in
the cortico-limbic structures, a series of synaptically
interconnected circuits linking the prefrontal cortex, amyg-
dala, ventral tegmental area (VTA), nucleus accumbens (NAc)
and ventral pallidum with the medial forebrain bundle
(MFB). Despite this complexity and apparently tightly
regulated balance, there is a remarkably high research
activity in the development of compounds for weight
management that act within the CNS. Some of the most
advanced preparations in development belong to this
category. However, the contribution of old molecules,
initially developed for other indications, is also considerable
in this group. Remarkable is also the emergence of
combination therapies in this category, aiming to modulate
different targets in parallel, while reducing the dose of the
individual compounds to minimize side effects. Table III
briefly summarizes the main representatives and targets of
this category. Note that many CNS compounds are
modulating different targets or pathways in parallel.
Compounds Predominantly Modulating Local
Availability of Dopamine, Norepinephrine
and Serotonin in the Brains
This group also comprises the amphetamine-related
compounds fenfluramine (Fig. 6) and dexfenfluramine,
which were banned in 1997. Another amphetamine
derivative, phentermine (Fig. 6), once popular in fen-phen
combinations with fenfluramine and dexfenfluramine, is
currently approved in the US as a short-term treatment for
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weight loss. Phentermine is thought to stimulate the release
of norepinephrine and dopamine (30). As will be discussed
later, the compound is now under investigation as part of a
combination preparation (QnexaR) together with topiramate.
Subitramine (Fig. 6) is one of the two currently approved
weight-loss drugs in the US. Since early 2010, it is no
longer on the market in Europe. The compound acts
centrally as an uptake inhibitor of norepinephrine, seroto-
nin and dopamine. The demethylated metabolites are more
active than the parent compound. Subitramine is consid-
ered an effective weight-loss drug, showing body-weight
reductions between 5 and 10% in most trials (30). Side
effects include constipation and increased blood pressure
and heart rate.
Bupropion (Fig. 7) is a dopamine and norepinephrine
reuptake inhibitor and has also antagonist activity for
Fig. 7 Chemical structures of bupropion (a dopamine and norepineph-
rine reuptake inhibitor with antagonist activity for nicotine receptors) and
tesofensine (a dopamine, norepinephrine and serotonin reuptake inhibitor
in development).
Table III Some Examples of Pharmacological Targets Within the CNS
Assumed (predominant-) target Mechanism of action Example(s)of compounds (late-stage development or approved)
Dopamine/norepinephrine/serotonina Inhibition of uptake Subitramine
Bupropion
Tesofensine
Stimulation of release Phentermine
GABA Stimulation of GABA activityb Topiramate (in combinations)b
Zonisamide (in combinations)b
Serotonin-receptor (5-HT2c) Agonist Lorcaserin
Serotonin-receptor (5-HT6) Agonist Several compounds in early clinical phase
MC4-receptor Agonist Preclinical/early clinical
MCH-receptor type 1 Antagonist NGD-4715
Histamine (H3-) receptor Antagonist Preclinical and early clinical phase
NPY (Y5) receptor Antagonist Velneperit
AgRP Inhibition TTP435
PTP1B Inhibition Trodusquemine
a often affecting different neurotransmitters with different relative potency
b combined with other mechanisms, partly unresolved
Fig. 6 Chemical structures of
some compounds predominantly
acting by increasing local concen-
trations of dopamine, norepi-
nephrine and 5-HT in the brain:
fenfluramine (banned in 1997),
phentermine, and sibutramine
(recently withdrawn in Europe).
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nicotine receptors (30,110,111). It was originally developed as
an antidepressant and for smoking cessation, for which it is
approved in the US, but later showed utility in the treatment
of obesity (110,111). Studies have shown that the compound
can cause effective, long-term (1-year) weight loss when
combined with lifestyle modification, and it appears to be
more effective in patients not suffering from depression (111).
It is also suggested that bupropion could serve as a valuable
adjunct therapy to elevate mood in depressed patients in
whom weight gain, secondary to antidepressant therapy, is
an issue (111). Bupropion is currently also under clinical
investigation in two different combinations, one together
with the anti-epileptic drug zonisamide (Empatic®) and the
other with the opioid antagonist naltrexone (Contrave®).
These will be discussed in a next section.
Tesofensine (Fig. 7) is a dopamine, norepinephrine and
serotonin reuptake inhibitor developed by the Danish
company Neurosearch. The compound has successfully
passed phase II clinical testing (ClinicalTrial.gov
NCT00394667), in which it showed dose-dependent weight
loss (112), and has just entered phase III testing (30).
Combination Therapies Based on Existing Drugs
Interestingly, two older compounds of the previously
described class of compound modulating levels of mono-
amines, phentermine and bupropion, are currently under-
going their renaissance in combination preparations with
other existing drugs. Two of these combinations, Contrave®
(bupropion plus naltrexone) and Qnexa® (phentermine plus
topiramate) have already passed phase III testing. With
the third combination, Empatic® (bupropion plus zonisa-
mide), phase III testing will probably start shortly. The
matching compounds in these combinations were initially
developed as anti-epileptic drugs (zonisamide and top-
iramate) or as opioid antagonist (naltrexone). Topiramate
and zonisamine are known to interact with different
pathways, including GABA-ergic transmission. However,
whilst GABA plays an important role in the brain, GABA-
related targets do not appear to have provided practical
strategies for weight management so far. The same holds
true for opioids. Although there is considerable evidence
that μ-, κ- and δ-opioid receptors located in the reward-
related brain areas are involved in control of food intake,
this has not resulted in new molecules for weight
management (30). One of the explanations might be that
opioid antagonists as monotherapy have a rather complex
effect on eating behavior, mainly affecting hedonic
components and not satiety or satiation (30). Furthermore,
the opioid system has many connections and functions
within the CNS, which also increase the risk for side effects
when single compounds would be used at pharmacolog-
ically active doses.
Phentermine Plus Topiramate (Qnexa®)
The amphetamine derivative phentermine (Fig. 6) is
currently approved in the US as a short-term treatment
for weight loss (recommended dose 37.5 mg/day), whereas
topiramate (Fig. 8) is indicated for treatment of seizures
(recommended dose 400 mg/day) or prevention of mi-
graine headaches (recommended dose 100 mg/day). The
use of topiramate for weight management is a typical
example of serendipity in the discovery of drugs in this area.
It was not only discovered incidentally as anti-convulsant,
but was also shown to possess anti-craving and weight loss
effects (108). The mechanism(s) by which topiramate
induces weight loss effects are still largely unknown. The
combination, given in a slow-release formulation intended
for once-daily administration allows lower doses of the
individual compounds and is reported to cause fewer side
effects than the individual compounds. Results from the
recent EQUIP phase III trial sponsored by Vivus Inc.
(Clintrial.gov NCT00554216), in which 1267 persons with
a mean BMI of 42 kg/m2 were enrolled for 56 weeks,
indicate that the combination of 15 mg phentermine with
92 mg topiramate resulted in a mean weight loss of 14.4%,
whereas persons in the placebo group lost 2.2% (113).
Results were also in agreement with the FDA efficacy
benchmarks in terms of % of persons showing more than
5, 10 or 15% weight loss. This was associated with
significantly different (from placebo) reduction in waist
circumference and systolic and diastolic blood pressure. In
another phase III study (QONQUER), the combination
Fig. 8 Structures of topiramate and zonisamide, originally developed as
anti-epileptic compounds. Currently under development in combination
preparations.
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showed beneficial effects on triglyceride levels and HbA1c.
No major side effects have been reported or safety issues
raised so far. However, taken the known side effects of both
drugs at higher doses (30), it is predictable that authorities
will be watchful in the further processes. Indeed, FDA has
recently (October 2010) declined to approve Qnexa based
on the current data, asking for more study results and more
information on possible risks.
Bupropion plus Zonisamide (Empatic®)
Bupropion (Fig. 7) has been discussed in the previous
section. The combination with the anti-epileptic compound
zonisamide (Fig. 8) has been reported to have higher
efficacy with fewer side effects. Like topiramate, zonisamide
is an anti-convulsant compound that has been shown to
induce weight loss (114). It is supposed to act via mechanisms
that are partly different from those of topiramate, affecting
GABA, serotonin, and dopamine-regulated processes (30).
In a phase IIb trial lasting 24 weeks, involving 729 obese
subjects, mean weight loss with Empatic-360 (bupropion
360 mg/zonisamide 360 mg) was 9.9% and 7.7% with
Empatic-120 (bupropion 360 mg/zonisamide 120 mg),
respectively. The placebo group lost 1.7% of their body
weight (111). In addition, significantly more subjects in the
groups receiving the combinations lost ≥5% of their
baseline weight as compared with subjects in the placebo
group. Adverse events were similar to those reported for
each of the individual drugs. This combination is antici-
pated to move to phase III testing soon.
Bupropion Plus Naltrexone (ContraveR)
This third combination of existing drugs combines bupro-
pion with the opioid antagonist naltrexone and is developed
by the same company (Orexigen Therapeutics, Inc.) as
Empatic®. Like bupropion, naltrexone is also already on
the market. Synergistic effects were found in preclinical
testing and during phase II studies. It has been suggested
that the μ- and κ-antagonist naltrexone inhibits a negative
feedback loop that limits the α-MSH response of POMC
neurons following stimulation by bupropion. The resulting
α-MSH then acts as an anorexigenic signal via stimulation
of the MCR4 receptor (see also next section). The company
has submitted an NDA to the FDA following a series of
successful phase III trials that were finished in 2009. In
these trials, the combination met the FDA efficacy
benchmark causing at least 5% loss of body weight in
approximately 50% of patients treated with Contrave-32
(bupropion 360 mg SR+naltrexone 32 mg SR) as com-
pared to 16–18% of placebo patients. This was accompa-
nied with improvements of cardiometabolic risk factors.
The company also announced that the combination shows
beneficial properties in obese persons with diabetes and
obese persons with major depression (115).
Serotonin (5-HT) Receptor Ligands
The inverse relation between an increased availability of
serotonin in certain brain areas and food intake has already
been recognized for a long time, for example from the effects
of fenfluramine and selective serotonin reuptake inhibitors like
fluoxetine. However, due to side effects, non-selective modu-
lation of brain serotonin levels were generally not regarded as
an attractive target for weight management. During further
investigations to untie the different serotonin actions to
achieve better selectivity, a number of 5-HT receptors were
identified as potential candidates (see (116) for review). Of
those, the 5-HT2C and 5-HT6 receptors have so far delivered
the most promising candidates.
5-HT2C Agonists
The role of the brain 5-HT2c receptors in reducing food
intake was discovered by the end of the last century while
investigating the mechanisms of action of fenfluramine in
rodents (117,118). As a result, several companies started to
develop selective 5-HT2C agonists as possible candidates for
obesity (116,119). Although a number of compounds have
reached phase II testing, selectivity for 5-HT2c over
(peripheral) 5-HT2B receptors and the development of
tolerance may limit their success (116). However, a
promising molecule is lorcaserin (APD356, Fig. 9), a
structural analogue of dexfenfluramine.
The compound is a selective 5-HT2C agonist with ~15-
fold and 100-fold selectivity over that for 5-HT2A and 5-
HT2B receptors, respectively (120). Its efficacy has been
demonstrated in a number of studies. For example, during
a two-week phase II trial with 469 obese persons (BMI 30–
45 kg/m2), lorcaserin caused dose-dependent weight loss up
to 3.3 kg (placebo adjusted) in the group receiving
lorcaserin 10 mg two times daily. The percentages of
patients completing the trial who lost ≥5% of their initial
body weight were 2.3, 12.8, 19.5, and 31.2% with placebo,
10 mg per day, 15 mg per day and 10 mg two times daily,
respectively (120). After completing a phase III clinical trial
program, the company Arena Pharmaceuticals has submit-
ted a New Drug Application to the FDA in December
2009, based on data from 18 clinical trials with, in total
8,576 patients, which were evaluated for periods up to two
Fig. 9 Lorcaserin, a selective
5-HT2C agonist currently in the
registration phase.
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years (121). However, in September–October 2010, the
FDA rejected the application because of safety issues that
had been found in the preclinical data files. The applicants
expressed their confidence in being able to alleviate these
concerns, but at this stage it is unclear what the con-
sequences for the further development of lorcaserin are.
5-HT6 Agonists
Another serotonin-associated target that is increasingly
receiving attention is the 5-HT6 receptor (see (116, 119)
for reviews). The 5-HT6 receptor is almost exclusively
distributed within the central nervous system, which is
rather unusual for a member of the serotonin receptor
family. This is considered an advantage, as this facilitates
selective modulation. The 5-HT6 receptor has also become
an attractive target for potential new antipsychotics and
antidepressants. Many new 5-HT6 ligands have been
synthesized with different structures (119). Among these, a
number of compounds have shown effects on food intake or
body weight in rodents, and some have entered clinical
testing. The next few years will be decisive in demonstrating
the potential of this target.
Dopaminergic Ligands
Compared to 5-HT receptors and despite the role of
dopamine in regulating eating behavior, dopamine receptors
do not appear to be considered as attractive targets at the
moment. Preclinical studies suggest that D3 antagonists can
be effective in reducing food intake (122). GlaxoSmithKline
is currently investigating the D3 antagonist GSK598809
for use with compulsive overeating (ClinicalTrials.gov
NCT01039454).
MC4R (Melanocortin 4 Receptor) Agonists
and MCH-R1 (Melanin-Concentrating Hormone
Receptor 1) Antagonists
The melanocortin system plays an important role in the
central regulation of energy balance (123). The POMC
(pro-opiomelanocortin) gene encodes several anorexigenic
peptides that can activate at least five melanocortin
receptor subtypes. These peptides include α-,β-,γ-melano-
cyte-stimulating hormone (α-MSH, β-MSH and γ-MSH)
and adrenocorticotropin (ACTH). Of the different recep-
tors, the melanocortin 4 receptor (MC4R) is receiving
considerable interest as a potential target. Several small-
molecule agonists have been synthesized. See for structures
for example (124) and for a very extensive list also (125).
The clinical usefulness of this group remains to be
established. Results with the MC4R agonist MK-0493
from MSD in humans were disappointing (126).
Melanin-concentrating hormone (MCH) is an endoge-
nous small cyclic peptide that increases food intake via
interaction with the MCH-R1 receptor. MCH-R1 antago-
nists have been shown to inhibit food-intake in rodents, and
several of such compounds have been synthesized
(125,127). Remarkably, cardiovascular side effects involving
hERG binding and the potential for subsequent drug-
induced QT prolongation have presented major hurdles in
a significant number of MCH-R1 research programs (127).
Nevertheless, some molecules, including NGD-4715
(Fig. 10), have reached phase II. Another example is BMS-
830216 (Bristol-Myers Squibb), which is also entering phase
II (ClinicalTrials.gov NCT00909766).
H3 Receptor Antagonists
Central histamine signaling has been implicated in appetite
regulation, and inhibition of H1 receptor signaling or
stimulation of H3 receptors may also play a role in the
weight gain associated with antipsychotic medication.
Histamine signaling is auto-regulated by the presynaptic
H3-histamine receptor, which inhibits histamine synthesis
and release when activated (128–130). Both H1-receptor
agonists and H3-receptor antagonists have been investigat-
ed as anti-obesity therapeutics. However, most attention
has focused on the development of antagonists for the H3-
receptor, since these are expressed almost exclusively in the
central nervous system. Several compounds have been
synthesized; examples are given in (128) and (129). In
preclinical testing, the selective H3-receptor antagonist, A-
331440 (Fig. 11), at oral dosages of 5 mg/kg and 15 mg/kg
twice daily, induced significant weight loss in mice (111).
Another example is HPP404 from Transtech Pharma
(http://www.ttpharma.com), which is also reported to be in
phase I. Many other H3 antagonists are in clinical
development for indications different from obesity
(128,129). The H3 antagonist SCH-497079, which was
acquired by Merck&Co, has undergone phase II testing for
weight management, but its status is presently unknown.
The compound betahistine (Histalean®, Fig. 11), which is
on the market in Canada and Europe for vertigo, has also
been claimed to decrease food intake via blockade of
Fig. 10 Structure of NGD-4715, a MCH-R1 antagonist presently in phase II.
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central H1 and H3 receptors. However, consistent evidence
for efficacy in humans appears to be lacking(131).
NPY Antagonists
Neuropeptide Y (NPY) is a centrally acting orexigenic
peptide that belongs to the same (pancreatic polypeptide-)
family as PYY and PP. Signaling at neuronal Y1 and Y5
receptors produces the orexigenic effects of NPY, whereas
Y2- and Y4-receptor signaling produces an anorexic
phenotype due to pre-synaptic inhibition of NPY release.
The latter two receptors are also the targets of the gut
hormones PYY, PP and their mimetics that have been
discussed in a previous section. Exploring the potential
utility of the Y1 and Y5 receptors as targets, several small-
molecule antagonists have been synthesized, for example by
the Merck laboratories (124). An orally active Y5-receptor
antagonist from Merck (MK-0557) was as unable to induce
clinically meaningful weight loss in a one-year clinical trial
(111). However, the Y5-receptor antagonist velneperit (S-
2367, Fig. 12) from Shionogi (http://www.shionogi.co.jp) is
still in development. In a phase II trial, it showed modest
but significant effects (111).
Agouti-Related Protein (AgRP)- Inhibitors
Similar to NPY, AgRP is an endogenous orexigenic protein
acting in the basal hypothalamus. Consequently, selective
inhibitors might also have potential in inhibiting food
intake. However, there do not seem to be many candidates
in advanced stages of development. An exception is
TTP435 from Transtech Pharma (http://www.ttpharma.
com), which is reported to be a selective inhibitor of AgRP
with oral activity and high brain penetration. Following
successful animal studies, the compound is currently in
phase II clinical trials.
Other CNS Compounds and Targets
A possible future target for weight management could
become the bombesin receptor subtype 3 (BRS-3). This is a
GPCR which is widely distributed in the brain but whose
natural ligand is still unknown. Recently, a group of
scientists from Merck reported the synthesis of a BRS-3
agonist that reduced food intake and increased metabolic
rate in mice (132).
Inhibitors of Protein Tyrosine Phosphatase (PTP1B)
This enzyme is widely expressed throughout the body. In
the brain, it negatively regulates leptin signaling and
appears to be involved in the development of leptin
resistance (133). As leptin resistance plays a role in obesity,
inhibition of central PTP1B activity may provide a way to
overcome this. In addition, peripheral PTP1B inhibition
might improve insulin sensitivity in muscle and liver.
Recently, Banno et al. (133) showed that PTP1B plays an
important role in POMC neurons in the hypothalamus. The
natural compound trodusquemine (Fig. 13) is a central and
peripheral inhibitor of PTP1B. It showed weight loss and
beneficial effects on fasting blood glucose, blood cholesterol
and triglyceride levels in obese animals (134–136).
The compound has been in development as MSI-1436
by Genaera, who ended phase I clinical studies in 2007.
Since this company has ended its business, its current status
and perspective are unclear, although the compound is
used as experimental tool.
COMPOUNDS AIMING TO REDUCE FAT MASS
In addition to reducing energy intake, different pharmaco-
logical approaches are being evaluated to reach weight
reduction or improve health by increasing energy expendi-
ture or by reducing or redistributing adipose tissue. The
latter may be useful to change “risky” (visceral) fat into less
risk-bearing fat depots. In the food supplement area, there
are many preparations claiming to help “burn” fat.
Although some compounds, including caffeine, ephedrine
and epigallocatechin gallate (EGCG), have been shown to
possess some activity, sustained effects are generally
Fig. 11 Structures of the selective H3-receptor antagonist, A-331440
and of betahistine.
Fig. 12 Chemical structure of velneperit, a Y5-receptor antagonist.
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disappointing (37). Nevertheless, targeting energy expendi-
ture (cellular bioenergetics), in particular adaptive thermo-
genesis, is regarded as a valuable option (137). Adaptive
thermogenesis is generated by mitochondria of skeletal
muscle and by brown adipose tissue (BAT) in response to
external stimuli. Until five years ago, it was generally assumed
that adult humans possess negligible amounts of BAT, which
did not make this tissue an interesting option for pharma-
cological intervention. However, recent findings have dem-
onstrated that adults maintain active BAT (138–140). As a
result, interest in BAT as a new target for human obesity has
also returned (137,141,142).
Examples of the rather heterogeneous group of com-
pounds targeting local or total body fat are listed in
Table IV.
Beta-3 Receptor Agonists
The β3-adrenergic receptor is expressed in adipocytes and
some other tissues. The discovery, during the early 80s, of
last century, of its role as a regulator of lipolysis and fatty
acid oxidation in rodents pushed many pharmaceutical
companies to start developing β3AR agonists for human
weight management (141). However, clinical studies in
humans did not meet the high expectations.
For example, the selective human β3-agonist, L-796568
(Fig. 14) failed to reduce weight or 24-h energy expenditure
over 28 days in overweight men (143). Similarly, no clear
effects of the β3-agonist compound TAK-377 (Fig. 14) were
found in a human trial (144). Recently, the development of
a combination of the β3 agonist L-377604 plus subitramine
was terminated. Compound KRP-204 (Fig. 14) appears to
be still in development for obesity (and also for other
indications), but its present status is unclear.
Some other β3 agonists, for example SR58611A (Fig. 14)
from Sanofi-Aventis, are now being investigated for use in
anxiety and depression. The lack of efficacy of β3 agonists
on human adipose tissue has been explained by the low
numbers of β3-adrenoreceptors on human adipocytes as
compared to mice or the weak effect of β3 activation on
lipolysis in general. Furthermore, many compounds suf-
fered from poor selectivity and unfavorable PK properties,
such as a low oral bioavailability (141). However, the recent
developments in the discovery of brown adipose tissue in
humans expressing the β3AR have generated new optimism
(137). There are indications that treatment with β3AR
agonists may increase the amount and activity of this brown
adipose tissue (141).
Selective Thyroid Hormone Mimetics
Thyroid hormone itself stimulates adaptive thermogenesis
and lipolysis, but its use as anti-obesity compound is
obsolete due to the many side effects, including tachycardia,
muscle wasting and loss of bone mass. However, a number
of selective thyroid hormone receptor (TR) subtype β-
agonists have been developed that may have potential as
anti-obesity and/or lipid-lowering agents. These include
KB-141 (eprotirome, Fig. 15), GC-1 (sobetirome, Fig. 15),
KB-2115 and MB07811.
These molecules possess pharmacological profiles differ-
ent from that of thyroid hormone (145–147). For example,
KB-141 was shown to have anti-obesity, lipid-lowering and
anti-diabetic effects in rodents, without causing tachycardia.
This suggests that selective TRβ activation could provide a
future strategy to attenuate features of the metabolic
Table IV Main Classes of Compounds Acting on Local or Total Body Fat
• Beta-3 adrenergic receptor agonists
• Selective thyroid hormone receptor subtype β-agonists
• Growth hormone analogues
• 11-β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors
• Sirtuin 1 activators
• Diazoxide
• Inihibitors of angiogenisis
• TGR5 agonists
Fig. 13 Structure of trodusquie-
mine, a natural PTP-1B inhibitor.
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syndrome (145). However, more studies are needed to
determine the therapeutic potential of this class, and there
appear to be no compounds having progressed beyond
phase I clinical trials at the moment (146).
Growth Hormone (GH) Analogues
The concept of using GH or its analogues to combat
obesity dates back several years. It was based on different
principles, including lower GH levels and a reduced
responsiveness to GH in obese persons, which is generally
restored after weight loss (111). However, when combined
with a hypocaloric diet, GH was not shown to have
additional benefits. In combination with an isoenergetic
diet, GH induced only a modest reduction in weight as
compared with placebo. Furthermore, several studies
reported a worsening of insulin resistance in subjects treated
with GH. A modified fragment of human GH, AOD9604,
has been in development for weight management. It had
been designed to mimic the lipolytic effects of GH without
producing growth effects. However, its development was
stopped in 2007 because of insufficient efficacy during a 24-
week trial with 536 subjects. Taken together, there seems to
be little enthusiasm left for GH as a target to reduce body
weight.
Inhibition of 11-Β Hydroxysteroid Dehydrogenase
Type 1
The 11-β hydroxysteroid dehydrogenase enzymes type 1
isoform (11β-HSD1) is currently receiving considerable
attention because of its possible role in the development
of the metabolic syndrome (148–152). This is amongst
others based on the observation that overlap exists in
patho-physiology and symptomology between Cushing
syndrome and the metabolic complications of visceral
obesity. The enzyme 11β-HSD1 primarily catalyzes the
reduction of hormonally inactive cortisone into the high-
Fig. 14 Structures of some β3—
adrenergic agonists investigated as
anti-obesity compounds.
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affinity ligand cortisol (or corticosterone in rodents)
(150,151). It is rather ubiquitously expressed throughout
the body, with highest levels in the liver followed by adipose
tissue and brain. Several natural compounds of both
endogenous and exogenous origin are known inhibitors of
11β-HSD1, including glycyrrhetinic acid from licorice root
and its synthetic hemisuccinyl ester, carbenoxolone (151).
However, most of these are unspecific, whilst enzyme and
also tissue specificity would be important prerequisites for
therapeutic usefulness in obesity and/or its metabolic
complications. Selective 11β- HSD1 inhibitors that are
effective in adipose tissue have shown positive results in
animal models and may also be efficacious in improving
insulin sensitivity and reducing weight in humans (150–
152). Several companies, including Biovitrum, Amgen,
AstraZeneca, Abbott, Merck, Pfizer, and Incyte have
developed 11β-HSD1 inhibitors, mainly for treatment of
type 2 diabetes but also for obesity (153–155). Some
structures are given in Fig. 16.
Although the development of the first selective 11β-
HSD1 inhibitor BVT-3498 (AMG-331) was terminated
during phase II testing, several other compounds have
reached the clinical phase. One of the most advanced is
INCB 13739 (structure not disclosed) from Incyte (156).
The next few years will be pivotal in showing whether this
target will be successful. The need for selectivity and the
risk of activation of the HPA axis have been suggested as
potential hurdles (154).
Sirtuin 1 as Potential Target in Obesity
SIRT1 belongs to the silent information regulator 2 (Sir2)
enzymes (or sirtuins) which have emerged as central players in
the regulation of critical metabolic pathways, such as insulin
secretion and lipid metabolism. Sirtuins regulate their targets
by modulating the activity of their partner proteins through
reversible de-acetylation. The most studied sirtuin is SIRT1
(see for example (157) and (158) for recent reviews). This
enzyme has been implicated in longevity and the beneficial
effects of caloric restriction. SIRT1 enhances fat mobilization
and lipolysis by binding to and repressing the expression of
PPARγ-regulated genes, including those mediating fat
storage. In addition, SIRT1 interacts with PGC-1α, inducing
the expression of mitochondrial genes involved in oxidative
metabolism and fatty acid oxidation. Resveratrol (Fig. 17)
has been proposed as a natural SIRT1 activator, in addition
to having other activities.
Following the discovery of SIRT1 and its role in
metabolism, several small-molecule SIRT1 activators (some
examples given in Fig. 17) have been synthesized with
structures different from that of resveratrol but with
considerably higher potency (159,160). A number of these
compounds were reported to improve metabolic function in
animal models of diabetes and obesity, suggesting that they
may have therapeutic potential. For example, SIRT 1720
(Fig. 17) was found to protect mice against diet-induced
obesity by enhancing oxidative metabolism in skeletal
muscle, liver and BAT (161).
In 2004, GlaxoSmithKline founded Sirtris Pharmaceut-
icals, a company focusing on the development of drugs
targeting SIRT1. Sirtris reports a number of compounds in
clinical development (162). However, recently Pacholec et
al. (163) suggested that resveratrol and a number of the
Sirtris compounds are not directly activating SIRT1. The
authors also questioned the beneficial effects of SRT1720 in
a rodent diabetes model and stated that the Sirtris
compounds and resveratrol are highly promiscuous com-
pounds having multiple targets. Similar to several other
classes described in this review, the coming years will show
whether the high expectations are justified.
Diazoxide
Diazoxide (Fig. 18) is a potassium channel activator that
opens the K+- ATP channels in pancreatic β-cells, thereby
inhibiting insulin secretion. Diazoxide is currently used to
treat hypoglycemia but may also have potential in hyper-
triglyceridemia and obesity.
Although some investigators suggest a beneficial effect of
diazoxide in obesity in combination with caloric restriction
and physical exercise (164), its usefulness as a target in
obesity is questioned by others (165). A controlled release
Fig. 15 Chemical structures of thyroid hormone (T3) and 2 selective
thyroid hormone receptor (TR) subtype β-agonists developed as anti-
obesity and/or lipid-lowering agents.
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formulation of its choline salt is under development by
Essential Therapeutics (http://essentialistherapeutics.com/
pages/products.php).
Angiogenesisis Inhibitors
Adipose tissue is highly vascularized, and expansion requires
the formation of new capillaries. Therefore, the use of
selective inhibitors of angiogenisis has been proposed as a
possible approach to reduce fat tissue (149,166,167). An
interesting proof-of-concept study in mice was described
by Rupnick et al. (166), who showed that systemic anti-
angiogenic agents caused dose-dependent, reversible weight
reduction and adipose tissue loss. However, an important
challenge is to target adipose tissue resulting in “magic
bullets” that “melt fat” (168). This principle was shown by
Kolonin et al. (169) using a phage-display method in
mice. Molecular targets could include one or several of
the angiogenic factors secreted by adipocytes including
leptin, angiopoietins, HGF, GM-CSF, VEGF, FGF-2,
and TGF-β (170). One of the companies active in this
area is Korean AngioLab (http://angiolab.co.kr/), who
reports to develop a herbal preparation named ALS-
L1023 for this purpose.
TGR5
TGR5 is a G-protein coupled receptor that is activated by
bile acids, including lithocholic acid and deoxycholic acid
(171). TGR5 is widely expressed in the body, in particular
in metabolic tissues such as liver, muscle, intestine, and
brown adipose tissue. Interest in TGR5 as potential target
for obesity and diabetes has been raised, since receptor
activation was shown to be connected with an increase in
energy expenditure, a reduction of diet-induced obesity and
an increase of GLP-1 release in vitro (172,173). A number of
companies have started to synthesize and test selective
TGR5 agonists, with bile acid-derived or non-bile acid
structures (171,174). One of these is the semi-synthetic
TGR5 agonist INT-777, which was found to increase
energy expenditure and reduce weight gain in mice on a
high-fat diet (173). Furthermore, insulin sensitivity in obese
mice was improved with INT-777. The development of
TGR5 agonists is still in its infancy, and although results so
far look promising, it is too early to draw conclusions on the
potential of this target. There are no drug candidates yet
that have reached the clinical phase. As TGR5 seems to be
involved in a rather broad range of processes (171), more
insight in potential off-target effects will also be needed.
Fig. 16 Examples of some 11β-
HSD1 inhibitors.
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CONCLUSIONS
The rising obesity figures and associated health complica-
tions present unmet medical needs for safe and effective
new drug therapies. As illustrated in this review, a
remarkably wide diversity of targets and compounds is
presently being investigated. Despite the failures of the
past, for example with rimonabant and its analogues,
industry is prepared to take considerable risks. Remarkably,
combinations of existing CNS drugs (topiramate, zonisa-
mide, phentermine and bupropion) are among the most
advanced in development. In general and in spite of the
risks for side effects, CNS targets, including 5-HT, H3 and
Y-receptors, continue to be considered as promising. This is
amongst others due to the fact that for the time being the
largest effects are expected from central intervention.
Compounds acting on peripheral targets might offer
advantages in terms of side effects. Apart from the GLP-1
analogues liraglutide and exenatide and the combination
of pramlintide with metraleptin, peptide drugs mimicking
satiety hormones have not met the expectations so far.
However, better oral, intranasal, and transdermal formula-
tions could help to enhance the efficacy of such approaches.
Among the targets within the gut, those that stimulate the
release of GLP-1 seem to be the most promising at the
moment. Of particular interest is the GPR119 receptor. As
also described in this review, the endocannabinoid system
as target may see a revival during the coming years. Being
an alternative to what is currently the only worldwide approved
Fig. 18 Chemical structure of
diazoxide.
Fig. 17 Chemical structure of
resveratrol and 3 first generation
small-molecule SIRT1 activators.
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lipase inhibitor drug orlistat, the development of new lipase
inhibitor cetilistat seems to be one of the least risky. Other
approaches, such as MTP inhibition, need further proof of
principle. The value of other potential targets in the battle
against obesity, including 11β-HSD1, SIRT 1, TGR 5 and
the modulation of intestinal flora, will become clear during
the coming few years. Combination therapies, possibly
including drug-food combinations, not only offer the
advantage of multi-target therapy with sometimes higher
efficacy, but may also reduce side effects and risks. In
particular, for the preparations acting within the CNS, the
coming years will be crucial to see whether side effects
remain acceptable. Looking at the history of weight loss
drugs, it is understandable that authorities will be watchful.
Obesity is not regarded as a life-threatening disease, and, if
effective, anti-obesity drugs will be prescribed to a large and
diverse group of people. Furthermore, considerable off-
label use and distribution via the Internet and other
channels is to be expected. Given the high activity in this
field of research and notwithstanding the possible risks for
failures, it seems obvious that the therapeutic arsenal of
weight management drugs and other compounds used in
obesity will change considerably in the coming five years.
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